Next Article in Journal
Improved Precision of COPD Exacerbation Detection in Night-Time Cough Monitoring
Previous Article in Journal
Effect of Photobiomodulation on Post-Endodontic Pain Following Single-Visit Treatment: A Randomized Double-Blind Clinical Trial
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JPM
Volume 15
Issue 8
10.3390/jpm15080348
jpm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Validity and Reliability of the Singer Reflux Symptom Score (sRSS)

by
Jérôme R. Lechien
1,2,3,4
1
Department of Surgery, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), B7000 Mons, Belgium
2
Department of Otolaryngology Head Neck Surgery, CHU Saint-Pierre, B1000 Brussels, Belgium
3
Department of Otolaryngology-Head & Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), 92150 Paris, France
4
Department of Otolaryngology, Elsan Hospital, 75008 Paris, France
J. Pers. Med. 2025, 15(8), 348; https://doi.org/10.3390/jpm15080348
Submission received: 1 June 2025 / Revised: 19 July 2025 / Accepted: 28 July 2025 / Published: 2 August 2025
(This article belongs to the Special Issue Otolaryngology in Clinical Practice: The Necessity of Personalized Medicine)
Browse Figures
Review Reports Versions Notes

Abstract

Objectives: To investigate the reliability and validity of the Singer Reflux Symptom Score (sRSS), a new patient-reported outcome questionnaire documenting the severity of reflux symptoms in singing voice is proposed. Methods: Amateur and professional singers consulting the European Reflux Clinic for laryngopharyngeal reflux disease (LPRD) symptoms and findings were prospectively recruited from January 2022 to February 2023. The diagnosis was based on a Reflux Symptom Score (RSS) > 13 and Reflux Sign Assessment (RSA) > 14. A control group of asymptomatic singer subjects was recruited from the University of Mons. The sRSS was rated within a 7-day period to assess test–retest reliability. Internal consistency was measured using Cronbach’s α in patients and controls. A correlation analysis was performed between sRSS and Singing Voice Handicap Index (sVHI) to evaluate convergent validity. Responsiveness to change was evaluated through pre- to post-treatment sRSS changes. The sRSS threshold for suggesting a significant impact of LPRD on singing voice was determined by receiver operating characteristic (ROC) analysis. Results: Thirty-three singers with suspected LPRD (51.5% female; mean age: 51.8 ± 17.2 years) were consecutively recruited. Difficulty reaching high notes and vocal fatigue were the most prevalent LPRD-related singing complaints. The sRSS demonstrated high internal consistency (Cronbach-α = 0.832), test–retest reliability, and external validity (correlation with sVHI: r = 0.654; p = 0.015). Singers with suspected LPRD reported a significant higher sRSS compared to 68 controls. sRSS item and total scores significantly reduced from pre-treatment to 3 months post-treatment except for the abnormal voice breathiness item. ROC analysis revealed superior diagnostic accuracy for sRSS (AUC = 0.971) compared to sRSS-quality of life (AUC = 0.926), with an optimal cutoff at sRSS > 38.5 (sensitivity: 90.3%; specificity: 85.0%). Conclusions: The sRSS is a reliable and valid singer-reported outcome questionnaire for documenting singing symptoms associated with LPRD leading to personalized management of Singers. Future large-cohort studies are needed to evaluate its specificity for LPRD compared to other vocal fold disorders in singers.

1. Introduction

Laryngopharyngeal reflux disease (LPRD) is a disease of the upper aerodigestive tract resulting from the direct and/or indirect effects of gastroduodenal content reflux, inducing morphological and/or neurological changes in the upper aerodigestive tract [1]. The backflow of gastroduodenal content into the vocal folds may alter the vocal fold structure and biomechanical properties, leading to vocal fold function impairments in both speaking and singing voices [2,3]. LPRD has a high prevalence in laryngology, affecting approximately 50% of voice clinic patients [4]. As for many laryngopharyngeal conditions, LPRD is associated with non-specific symptoms, which supports the need to use validated patient-reported outcome questionnaire for improving patient management [1]. Professional voice users report a high LPRD incidence compared to the general population [5], which is attributed to their vocal demands, diet habits (late-night eating), and stress patterns [2,5,6]. Currently, no singer-reported outcome questionnaire specifically assessing LPRD-related symptoms in singing voice has yet been prospectively validated [2]. Indeed, currently available patient-reported outcome questionnaires documenting LPRD symptoms were not developed for singing voice, and some subtle symptoms found only during singing may not be detected/evaluated with existing questionnaires (e.g., the difficulty to reach high pitches, loss of voice intensity in singing). Developing such a patient-reported outcome questionnaire is important for detecting potential reflux consequences on singing voice, rating the LPRD impact on singing voice and measuring treatment outcomes for non-specific symptoms.
This study aims to investigate the reliability and validity of the Singer Reflux Symptom Score (sRSS), a newly developed patient-reported outcome questionnaire designed to document the severity of non-specific reflux symptoms in singing voice.

2. Materials and Methods

2.1. Development of Singer Reflux Symptom Score

The development of the sRSS started after a multidisciplinary panel discussion during the Congress of the International Federation of Otorhinolaryngological Societies (IFOS, Paris, 2016), in which international experts discussed dysphonia related to LPRD and the potential impact of gastroduodenal content reflux on speaking and singing voice. A summary of key singing symptoms was compiled at the end of the session, and the author of this paper (JRL) developed the French version of the sRSS after having developed and validated the Reflux Symptom Score (RSS) [7]. Six singers were invited to validate the main symptoms of sRSS and to rephrase some items. The French and English versions of the sRSS are available in Figure 1 and Figure 2. Note that the present validity study was conducted according to a checklist of recommendations and key characteristics to obtain valid and reliable patient-reported outcome measurements [7,8].
The sRSS consists of eight items, with the possibility to add a ninth item. Consistent with the RSS [7], the frequency and severity of each symptom are rated on a 5-point scale with each point of the frequency measure being precisely defined (Figure 1 and Figure 2). The severity score of each item is multiplied by the frequency score to obtain a symptom score ranging from 0 to 25. The sum of these symptom scores is calculated to obtain the final sRSS score, which ranges from 0 to 200 (225 in case of a ninth symptom). In addition to severity and frequency, sRSS evaluates the impact of symptoms on the singer’s quality of life (5-point Likert scale). The sRSS-quality of life score is calculated by the sum of each item score, ranging from 0 to 40. For this validity study, singers were invited to judge whether the questionnaire assessed all singing voice symptoms (yes/no).
The local ethics committee approved the study protocol (n°BE076201837630). All patients were invited to participate, and informed consent was obtained from those who enrolled in the study.

2.2. Subjects and Setting

Amateur and professional singers consulting the European Reflux Clinic (Brussels, Belgium) and Elsan Poitiers Polyclinic (Poitiers, France) for LPRD symptoms and findings were prospectively recruited from January 2022 to February 2023. The diagnosis was based on RSS > 13 [7] and Reflux Sign Assessment (RSA) > 14 [9], which were both validated criteria for the clinical diagnosis of LPRD in the general population. Nasovideolaryngostroboscopy was used for the RSA, considering oral, nasopharyngeal, laryngeal, and oral signs. A control group was composed of asymptomatic singers from the University of Mons. The 24 h hypopharyngeal–esophageal multichannel intraluminal impedance-pH testing (HEMII-pH) was not performed in singers because most feared the 24 h HEMII-pH probe tolerance, preferring to start an empirical therapeutic trial to achieve symptom relief whenever possible. Because LPRD diagnosis is based on the documentation of more than one pharyngeal reflux event at the 24 h HEMII-pH and the presence of LPRD symptoms (Dubai consensus) [1], asymptomatic individuals (no symptoms) did not undergo 24 h HEMII-pH either. The absence of LPRD symptoms (RSS > 13) may be consistent with the lack of LPRD diagnosis [1].
Singers and controls were excluded if they reported one of the following conditions: alcohol dependence, pregnancy, neurological or psychiatric illness, upper respiratory tract infection within the last month, current use of anti-reflux treatment (i.e., proton pump inhibitors (PPIs), histamine-H2 blockers, alginates and antacids), previous history of neck surgery or trauma, benign vocal fold lesions, malignancy, history of upper aerodigestive tract radiotherapy, untreated allergies, and inhaled corticosteroid-induced laryngitis (asthma).
The LPRD treatment included adherence to a standardized and validated anti-reflux diet [10], and the 3- to 6-month intake of post-meal alginates (Gaviscon Advance®, Reckitt Benckiser, Slough, UK) or antacid/magaldrate (Riopan®, Takeda, Zaventem, Belgium). Singers received a validated grid with diet recommendations and behavioral changes, which considered the patient’s personalized habits (late meals, alcohol intake after singing performances, etc.) [10].

2.3. Statistical Analyses

Statistical analyses were performed using the Statistical Package for the Social Sciences for Windows (SPSS version 29,0; IBM Corp, Armonk, NY, USA).
The reliability analysis included test–retest reliability and internal consistency. The sRSS was rated within a 7-day period to assess test–retest reliability with Spearman’s rank correlation coefficient. Internal consistency was assessed with the Cronbach-α for all sRSS items in patients and controls.
The validity analysis consisted of external and internal validity assessments. External validity was measured by correlations between sRSS, and the French version of the Singing Voice Handicap Index (sVHI) [11] with Spearman’s rank correlation coefficient. A statistical comparison between the sRSS of singers and asymptomatic individuals was carried out to evaluate internal validity (Mann–Whitney U test). Responsiveness to change was evaluated by comparing baseline and 3-month post-treatment sRSS scores (Wilcoxon signed-rank test). The sRSS threshold for supporting the presence and absence of LPRD-related singing symptoms was determined by receiver operating characteristic (ROC) analysis. A level of significance of p < 0.05 was used.

3. Results

Thirty-three singers with RSS > 13 and RSA > 14 were consecutively recruited from the European Reflux Clinic. The diagnosis was confirmed in two singers with one confounding laryngopharyngeal condition through 24 h HEMII-pH testing. The epidemiological, clinical, and singing characteristics are described in Table 1. There were 17 (51.5%) females and 16 (48.5%) males, respectively. The mean age was 51.8 ± 17.2 years. The tobacco, marijuana, and alcohol consumption details are described in Table 1. There were eight (24.2%) professional singers. Most singers were soloists (n = 27, 81.8%). The primary voice classifications in females and males were mezzo-soprano (n = 9, 27.3%) and tenor (n = 5, 15.2%). A small number of singers carried out cool-down exercise after singing (n = 5, 15.2%), while 15 (45.4%) started singing with a warmup. The primary musical/singing styles were classical, pop, pop-rock, and modern singing styles (Table 1). A control group of amateur singers was composed (n = 68; 50 (73.5%) females; age range: 18–32).
The prevalence of singing symptoms associated with LPRD are reported in Table 2. The difficulty to reach high notes and vocal fatigue/lack of vocal resistance were the two most prevalent complaints. The sRSS internal consistency analysis reported an adequate Cronbach-α (=0.832). Test–retest analysis was adequate for all sRSS items and total scores (Table 3). The intraclass correlation analysis reported adequate consistency for the test–retest reliability of the total sRSS (ICC: 0.736). The external analysis reported a significant positive correlation between sRSS and sVHI (r = 0.654; p = 0.015). The comparison between singers and individuals without LPRD symptoms (RSS < 13) demonstrated significantly higher item and total sRSS scores in LPRD singers compared to controls (Table 4), which indicated a high internal validity (Table 4). The pre- to post-treatment evolution of sRSS item, total, and QoL scores is reported in Table 4. Except for the abnormal voice breathiness item, all symptoms demonstrated a significant reduction after a 3-month treatment combining diet, lifestyle changes, and post-meal alginate (Table 4). The ROC curve of sRSS and sRSS-QoL is reported in Figure 3. The area under the curve values of sRSS and sRSS-QoL were 0.971 and 0.926, supporting the superiority of sRSS for determining the LPRD diagnosis. According to the Youden index, a sRSS > 38.5 reported a sensitivity of 90.3% and a specificity of 85.0%, respectively.

4. Discussion

The development of a singer-reported outcome questionnaire documenting the impact of LPRD on singing voice is warranted given the high prevalence of LPRD in singers, the potentially subtle singing symptoms primarily undetected and unattributed to LPRD, the need to precisely evaluate pre- to post-treatment changes in non-specific symptoms, and the significant impact of LPRD on singers’ careers [12,13,14,15,16].
The sRSS internal consistency analysis reported an adequate Cronbach-α (α = 0.832). The sRSS is the first clinical instrument developed prospectively for documenting LPRD-related singing symptoms, which limits the discussion of our results with similar instruments. However, in 2022, Nacci et al. proposed a revised Italian version of sVHI adapted to LPRD, combining Reflux Symptom Index outcomes with selected sVHI items [12,13]. In these two cross-sectional studies, authors reported a Cronbach’s alpha coefficient of 0.87 for all combined items, with item-total correlation coefficients for each item ranging from 0.461 to 0.670 [12]. In the same vein, the sRSS internal consistency is comparable to those of other singing patient-reported outcome questionnaires, such as the French (α = 0.80) [11], Greek (α = 0.960) [17], Italian (α = 0.853) [18], and Japanese (α = 0.981) [19] versions of the sVHI.
Our study suggests an adequate and moderate sRSS external validity regarding the significant association between sRSS and the French version of the sVHI (r = 0.654). Nacci et al. similarly observed a significant positive relationship between Reflux Symptom Index (not adapted to singers) and Singing Voice Handicap Index total score in a cohort of 159 singers (r = 0.474) [13]. Okui et al. reported a significant positive association between the Japanese sVHI and a visual analog scale score (r = 0.736) as external validity [19]. Note there was no external validity analysis in the other above-mentioned sVHI.
Item and total sRSS scores were significantly higher in singers with suspected LPRD compared to controls, which supports adequate internal validity. Internal validity refers to the extent to which the patient-reported outcome questionnaire accurately evaluates what it is intended to evaluate and ensures that observed changes or differences are truly due to the independent variable being manipulated, rather than other factors. The adequate sRSS internal validity data corroborate those of the Greek [17] and Japanese [19] sVHI studies, while Morsomme et al. did not find significant differences between patients and controls for the French sVHI [11].
The test–retest reliability measures the consistency of a clinical instrument over time when applied to the same individual. The sRSS test–retest reliability results demonstrated adequate values for items and total sRSS (r = 0.515–0.990), which corroborates the findings of some sVHI studies [11,17,18]. Giannopoulou et al. reported a correlation coefficient of 0.859 for the test–retest Greek sVHI [17]. In the French and Japanese sVHI studies, Morsomme et al. and Okui et al. reported test–retest validity coefficients of 0.878 and 0.93, respectively [11,19].
A limited number of studies evaluated pre- to post-treatment changes in sVHI scores. In this study, the sRSS demonstrated adequate responsiveness to change despite the small sample size. Cohen et al. evaluated the treatment responsiveness of the English sVHI in 30 singers, demonstrating a significant reduction in sVHI scores after treatment, and a significant correlation between Voice Handicap Index change and sVHI change (r = 0.71) from pre- to post-treatment [20]. A ROC curve analysis was conducted to define the threshold of sRSS associated with the highest sensitivity and specificity in detecting LPRD-related singing symptoms. Our analysis suggests a threshold of sRSS > 38.5 for the French version. Nacci et al. similarly investigated the ROC analysis of their reflux-adapted voice handicap index. The sensitivity and specificity of SVHI-12-LPR were 83.3% and 69.1% for the suspected diagnosis of LPRD with a cut-off score of 15 [12].
To the best of our knowledge, the sRSS is the first singer-reported outcome questionnaire prospectively developed for evaluating LPRD-associated singing symptoms, which is the primary strength of this study. The small sample size (singers), the lack of subgroup analysis (amateurs versus professionals, choristers versus soloists), and the absence of confirmation of LPRD diagnosis at the 24 h HEMII-pH are the main limitations. In clinical practice, it remains difficult to have full adherence from singers for 24 h HEMII due to their concerns about having a probe in their laryngopharynx for 24 h, potential tolerance issues, and their wish for rapid therapeutic intervention. Despite this reality, the lack of HEMII-pH monitoring limits the drawing of valid conclusions regarding the risk of having included patients with unknown confounding conditions associated with LPRD-like symptoms but no actual LPRD. Indeed, allergy [21,22,23], chronic rhinitis [24,25,26], chronic rhinosinusitis [27,28,29,30], tobacco-induced laryngitis [31], non-reflux chronic cough [32,33,34], or inhaled corticosteroid laryngitis [35] may lead to similar symptoms or findings compared with LPRD. The small number of singers is also an additional limitation in the drawing of valid conclusions.
Although the validation of new questionnaires typically requires comparison with asymptomatic individuals, future studies could evaluate the specificity of the sRSS in detecting LPRD in singers through comparative studies including various groups of singers with different voice disorders and multidimensional voice quality evaluations [36,37,38,39]. These studies are important to identify potential clinical differences across vocal fold disorders and to investigate the non-specificity pattern of most LPRD-related classical and singing symptoms, which are related to non-specific inflammation of vocal folds. Authors should discuss the results and how they can be interpreted from the perspective of previous studies and of the working hypotheses. The findings and their implications should be discussed in the broadest context possible. Future research directions may also be highlighted.

5. Conclusions

The sRSS is a reliable and valid singer-reported outcome questionnaire for screening potential singing symptoms associated with LPRD, documenting non-specific LPRD singing symptoms in symptomatic singers, and evaluating symptom changes through personalized management. An sRSS > 38.5 may be suggestive of LPRD, reporting high sensitivity and specificity, and can be used in clinical practice. Future large-cohort studies are needed to evaluate its specificity for LPRD compared to other vocal fold disorders in singers.

Funding

This research received no external funding.

Institutional Review Board Statement

The local ethics committee approved the study protocol (n°BE076201837630).

Informed Consent Statement

Patients and controls were invited to participate, and informed consent was obtained from those who enrolled in the study.

Data Availability Statement

Data are available on request.

Acknowledgments

Denis Deltenre and Anne Trelcat for the database management. Camille Finck for the proposition of some SRSS items in 2016. Students of UMONS for the calibration of the draft of SRSS. François Bobin, a retired laryngologist, for recruiting patients in Elsan.

Conflicts of Interest

The author declares no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
LPRDLaryngopharyngeal reflux disease
sRSSSinger Reflux Symptom Score
HEMII-pHHypopharyngeal–esophageal multichannel intraluminal impedance-pH testing
sVHISinging Voice Handicap Index

References

  1. Lechien, J.R.; Vaezi, M.F.; Chan, W.W.; Allen, J.E.; Karkos, P.D.; Saussez, S.; Altman, K.W.; Amin, M.R.; Ayad, T.; Barillari, M.R.; et al. The Dubai Definition and Diagnostic Criteria of Laryngopharyngeal Reflux: The IFOS Consensus. Laryngoscope 2024, 134, 1614–1624. [Google Scholar] [CrossRef] [PubMed]
  2. Lechien, J.R.; Briganti, G. Reflux Disease in Singers: A Systematic Review. J. Voice 2024, in press. [Google Scholar] [CrossRef]
  3. Lechien, J.R.; Saussez, S.; Harmegnies, B.; Finck, C.; Burns, J.A. Laryngopharyngeal Reflux and Voice Disorders: A Multifactorial Model of Etiology and Pathophysiology. J. Voice 2017, 31, 733–752. [Google Scholar] [CrossRef]
  4. Koufman, J.A.; Amin, M.R.; Panetti, M. Prevalence of reflux in 113 consecutive patients with laryngeal and voice disorders. Otolaryngol. Head Neck Surg. 2000, 123, 385–388. [Google Scholar] [CrossRef]
  5. Robotti, C.; Schindler, A.; Lechien, J.R.; Di Sabatino, A.; Capobianco, S.; Schindler, A.; Ottaviani, F.; Sims, H.S.; Bertino, G.; Benazzo, M.; et al. Prevalence of Laryngopharyngeal Reflux Symptoms, Dysphonia, and Vocal Tract Discomfort in Amateur Choir Singers. J. Voice 2023, 37, 932–944. [Google Scholar] [CrossRef]
  6. Cammarota, G.; Masala, G.; Cianci, R.; Palli, D.; Capaccio, P.; Schindler, A.; Cuoco, L.; Galli, J.; Ierardi, E.; Cannizzaro, O.; et al. Reflux symptoms in professional opera choristers. Gastroenterology 2007, 132, 890–898. [Google Scholar] [CrossRef] [PubMed]
  7. Lechien, J.R.; Bobin, F.; Muls, V.; Thill, M.P.; Horoi, M.; Ostermann, K.; Huet, K.; Harmegnies, B.; Dequanter, D.; Dapri, G.; et al. Validity and reliability of the reflux symptom score. Laryngoscope 2020, 130, E98–E107. [Google Scholar] [CrossRef]
  8. Kang, Y.; Guan, T.; Chen, X.; Zhang, Y. Patient-Reported Experience Measures in Adult Inpatient Settings: A Systematic Review. J. Nurs. Manag. 2024, 2024, 5166392. [Google Scholar] [CrossRef]
  9. Lechien, J.R.; Rodriguez Ruiz, A.; Dequanter, D.; Bobin, F.; Mouawad, F.; Muls, V.; Huet, K.; Harmegnies, B.; Remacle, S.; Finck, C.; et al. Validity and Reliability of the Reflux Sign Assessment. Ann. Otol. Rhinol. Laryngol. 2020, 129, 313–325. [Google Scholar] [CrossRef]
  10. Daniero, J.J. Decision Making in the Managment of Laryngopharyngeal Reflux Disease: Antacids, Alginates, and the Role of Diet. Otolaryngol. Clin. N. Am. 2025, 58, 519–527. [Google Scholar] [CrossRef] [PubMed]
  11. Morsomme, D.; Gaspar, M.; Jamart, J.; Remacle, M.; Verduyckt, I. Voice handicap index adapted to the singing voice. Rev. Laryngol. Otol. Rhinol. 2007, 128, 305–314. [Google Scholar]
  12. Nacci, A.; Bastiani, L.; Barillari, M.R.; Martinelli, M.; Lechien, J.R.; Simoni, F.; Berrettini, S.; Fattori, B. Reflux Symptom Index (RSI) and Singing Voice Handicap Index (SVHI) in Singing Students: A Pilot Study. J. Voice 2022, 36, 288.e25–288.e34. [Google Scholar] [CrossRef]
  13. Nacci, A.; Capobianco, S.; Mazzoni, L.; Fattori, B.; Barillari, M.R.; Genovese, E.; Berrettini, S.; Bastiani, L. Development of a New Self-Assessment Tool for Laryngopharyngeal RefluxScreening in Singers (SVHI-12-LPR). Folia Phoniatr. Logop. 2023, 75, 284–294. [Google Scholar] [CrossRef]
  14. Campagnolo, A.M.; Benninger, M.S.; Priston, P.; Assunção, A. Dysphonia in Performers: Prevalence of Vocal Lesions and Voice Emergencies in a Private Otorhinolaryngology Practice. J. Voice 2023, 37, 415–418. [Google Scholar] [CrossRef] [PubMed]
  15. Korn, G.P.; Azevedo, R.R.; Monteiro, J.C.; Pinheiro, D.S.; Park, S.W.; Biase, N.G. Difficulty producing high-pitched sounds in singing: Correlations with laryngostroboscopy and electromyographic findings. Braz. J. Otorhinolaryngol. 2020, 86, 669–675. [Google Scholar] [CrossRef] [PubMed]
  16. Dhar, S.; Mattioni, J.; Sataloff, R.T. Endoscopic Findings in a Professional Singer with Frequent Throat Clearing. Ear Nose Throat J. 2019, 98, 128. [Google Scholar] [CrossRef]
  17. Giannopoulou, J.; Papadopoulou, E.; Bibas, A.; Papathanasiou, I. Validation of the Singing Voice Handicap Index in Greek Singers: Normal and Voice-Disordered Participants. J. Voice 2025, in press. [Google Scholar] [CrossRef]
  18. Nacci, A.; Barillari, M.R.; Capobianco, S.; Fattori, B.; Berrettini, S.; Tonacci, A.; Minichilli, F.; Bastiani, L. Adaptation and validation of the Italian Singing Voice Handicap Index-10 (SVHI-10-IT). Acta Otorhinolaryngol. Ital. 2023, 43, 114–122. [Google Scholar] [CrossRef]
  19. Okui, A.; Nimura, Y.; Komazawa, D.; Kanazawa, T.; Konomi, U.; Hirosaki, M.; Okano, M.; Nishida, M.; Watanabe, Y. Validation of the Japanese Version of the Singing Voice Handicap Index. J. Voice 2024, 38, 544.e15–544.e21. [Google Scholar] [CrossRef]
  20. Cohen, S.M.; Witsell, D.L.; Scearce, L.; Vess, G.; Banka, C. Treatment responsiveness of the Singing Voice Handicap Index. Laryngoscope 2008, 118, 1705–1708. [Google Scholar] [CrossRef] [PubMed]
  21. Sui, H.; Luo, Z.; Zhang, X.; Zhang, J.; Zhen, Z.; Ding, T. The influence of saliva pepsin concentration on subjective severity of seasonal allergic rhinitis. Acta Otolaryngol. 2025, 145, 329–333. [Google Scholar] [CrossRef]
  22. Kakaje, A.; Alhalabi, M.M.; Alyousbashi, A.; Ghareeb, A. Allergic rhinitis, asthma and laryngopharyngeal reflux disease: A cross-sectional study on their reciprocal relations. Sci. Rep. 2021, 11, 2870. [Google Scholar] [CrossRef]
  23. Eren, E.; Arslanoğlu, S.; Aktaş, A.; Kopar, A.; Ciğer, E.; Önal, K.; Katılmiş, H. Factors confusing the diagnosis of laryngopharyngeal reflux: The role of allergic rhinitis and inter-rater variability of laryngeal findings. Eur. Arch. Otorhinolaryngol. 2014, 271, 743–747. [Google Scholar] [CrossRef] [PubMed]
  24. Eckley, C.A.; Tangerina, R. Using RSI and RFS scores to differentiate between reflux-related and other causes of chronic laryngitis. Braz. J. Otorhinolaryngol. 2023, 89, 54–59. [Google Scholar] [CrossRef] [PubMed]
  25. Tarmizi, N.E.; Hamizan, A.W.; Ng, C.S.; Gendeh, H.S.; Guan, L.S.; Zahedi, F.D.; Baki, M.M.; Husain, S. The Nasal Endoscopic Features of Postnasal Drip: A Cross Sectional Study. Int. Arch. Otorhinolaryngol. 2023, 28, e95–e100. [Google Scholar] [CrossRef]
  26. Smallwood, D.; Ledford, D.; Kennedy, D.; Lockey, R. Postnasal Drip. J. Allergy Clin. Immunol. Pract. 2024, 12, 1472–1478. [Google Scholar] [CrossRef]
  27. Brown, H.J.; Kuhar, H.N.; Plitt, M.A.; Husain, I.; Batra, P.S.; Tajudeen, B.A. The Impact of Laryngopharyngeal Reflux on Patient-reported Measures of Chronic Rhinosinusitis. Ann. Otol. Rhinol. Laryngol. 2020, 129, 886–893. [Google Scholar] [CrossRef] [PubMed]
  28. Aldajani, A.; Alhussain, F.; Mesallam, T.; AbaAlkhail, M.; Alojayri, R.; Bassam, H.; Alotaibi, O.; Alqahtani, M.; Alsaleh, S. Association Between Chronic Rhinosinusitis and Reflux Diseases in Adults: A Systematic Review and Meta-Analysis. Am. J. Rhinol. Allergy 2024, 38, 47–59. [Google Scholar] [CrossRef]
  29. Yeo, N.K.; Park, S.J.; An, T.H. Laryngopharyngeal reflux in chronic rhinosinusitis patients and the role of endoscopic sinus surgery. Auris Nasus Larynx 2022, 49, 663–669. [Google Scholar] [CrossRef]
  30. Anzić, S.A.; Turkalj, M.; Župan, A.; Labor, M.; Plavec, D.; Baudoin, T. Eight weeks of omeprazole 20 mg significantly reduces both laryngopharyngeal reflux and comorbid chronic rhinosinusitis signs and symptoms: Randomised, double-blind, placebo-controlled trial. Clin. Otolaryngol. 2018, 43, 496–501. [Google Scholar] [CrossRef]
  31. Kayalı Dinc, A.S.; Cayonu, M.; Sengezer, T.; Sahin, M.M. Smoking Cessation Improves the Symptoms and the Findings of Laryngeal Irritation. Ear Nose Throat J. 2020, 99, 124–127. [Google Scholar] [CrossRef]
  32. Arai, Y.; Okuyama, K.; Onishi, Y.; Schelfhout, J.; Tokita, S.; Kubo, T. Clinical characteristics and drug utilisation patterns in patients with chroniccough: A retrospective cohort study using a Japanese claims database. BMC Pulm. Med. 2022, 22, 429. [Google Scholar] [CrossRef]
  33. Lilly, G.L.; Carroll, T.; Pietsch, K.; Dhillon, V.; Bryson, P.C.; Akst, L.M. Refractory Chronic Cough: A State-of-the-Art Review for Otolaryngologists. Otolaryngol. Head Neck Surg. 2025, 172, 419–435. [Google Scholar] [CrossRef] [PubMed]
  34. Eapen, A.A.; Gupta, M.R.; Lockey, R.F.; Bardin, P.G.; Baptist, A.P. Gastroesophageal reflux disease, laryngopharyngeal reflux, and vocal cord dysfunction/inducible laryngeal obstruction-overlapping conditions that affect asthma. J. Allergy Clin. Immunol. 2024, 154, 1369–1377. [Google Scholar] [CrossRef]
  35. Koshiyama, S.; Tanimura, K.; Ito, K.; Funayama, S.; Hira, D.; Komase, Y.; Sato, S. Gastroesophageal reflux-like symptoms are associated with hyposalivation and oropharyngeal problems in patients with asthma. Respir. Investig. 2021, 59, 114–119. [Google Scholar] [CrossRef]
  36. Lloyd, A.T.; Ruddy, B.H.; Silverman, E.; Lewis, V.M.; Lehman, J.J. Quantifying Laryngopharyngeal Reflux in Singers: Perceptual and Objective Findings. BioMed Res. Int. 2017, 2017, 3918214. [Google Scholar] [CrossRef] [PubMed]
  37. Myint, C.; Moore, J.E.; Hu, A.; Jaworek, A.J.; Sataloff, R.T. A Comparison of Initial and Subsequent Follow-Up Strobovideolaryngoscopic Examinations in Singers. J. Voice 2016, 30, 472–477. [Google Scholar] [CrossRef] [PubMed]
  38. Butte, C.J.; Zhang, Y.; Song, H.; Jiang, J.J. Perturbation and nonlinear dynamic analysis of different singing styles. J. Voice 2009, 23, 647–652. [Google Scholar] [CrossRef]
  39. Bunch, M.; Chapman, J. Taxonomy of singers used as subjects in scientific research. J. Voice 2000, 14, 363–369. [Google Scholar] [CrossRef]
Jpm 15 00348 g001
Figure 1. The French version of the Singer Reflux Symptom Score. The severity score of each item is multiplied by the frequency score to obtain a symptom score ranging from 0 to 25. The sum of these symptom scores is calculated to obtain the final sRSS score, which ranges from 0 to 200 (225 in case of a ninth symptom). In addition to severity and frequency, sRSS evaluates the impact of symptoms on the singer’s quality of life (5-point Likert scale). The sRSS-quality of life score is calculated by the sum of each item score, ranging from 0 to 40.
Figure 1. The French version of the Singer Reflux Symptom Score. The severity score of each item is multiplied by the frequency score to obtain a symptom score ranging from 0 to 25. The sum of these symptom scores is calculated to obtain the final sRSS score, which ranges from 0 to 200 (225 in case of a ninth symptom). In addition to severity and frequency, sRSS evaluates the impact of symptoms on the singer’s quality of life (5-point Likert scale). The sRSS-quality of life score is calculated by the sum of each item score, ranging from 0 to 40.
Jpm 15 00348 g001
Jpm 15 00348 g002
Figure 2. The English version of the Singer Reflux Symptom Score. The English version is not yet validated.
Figure 2. The English version of the Singer Reflux Symptom Score. The English version is not yet validated.
Jpm 15 00348 g002
Jpm 15 00348 g003
Figure 3. ROC Curve.
Figure 3. ROC Curve.
Jpm 15 00348 g003
Table 1. Demographics, singing, and clinical outcomes of studies.
Table 1. Demographics, singing, and clinical outcomes of studies.
DemographicsPatients (n = 33)
Mean age (SD)51.8 ± 17.2 
Body mass index (mean, SD)27.2 ± 8.0
Gender (N, %) 
 Females17 (51.5)
 Males16 (48.5)
Smoker (current Cig/d) and smoking history (Paq. Year)3 (9.1)
Cannabis consumption1 (3.0)
Alcohol (daily consumption)3 (9.1)
 Alcohol (mean and SD for unit/day in consumers)0.2 ± 0.6
 Coffee/caffeine drink/day8 (24.2)
Singer types 
 Soloist27 (81.8)
 Chorister6 (18.2)
Voice range/classification 
Femalesn = 17
 Soprano5 (15.2)
 Mezzo-soprano9 (27.3)
 Alto1 (3.0)
 Several ranges2 (6.1)
Malesn = 16
 Tenor5 (15.2)
 Baritone4 (12.1)
 Bass1 (3.0)
 Several ranges6 (18.2)
Singing habits 
Habit of performing with amplification (microphone)2 (6.1)
Warm up before singing 15 (45.5)
Cool down after singing5 (15.2)
Involvement in professional singing activities 8 (24.2)
Musical/Singing styles 
 Classical12 (36.4)
 Pop4 (12.1)
 Rock/pop-rock3 (9.1)
 Gospel2 (6.1)
 Jazz1 (3.0)
 Opera1 (3.0)
 Modern3 (9.1)
 Several styles7 (21.2)
Abbreviations: SD = standard deviation.
Table 2. Symptom prevalence in singers.
Table 2. Symptom prevalence in singers.
Singer Reflux Symptom Score OutcomesPrevalence (N, %)
Hoarseness31 (93.9)
Abnormal voice breathiness20 (60.6)
Difficulty to reach high pitch/notes32 (97.0)
Additional effort during singing31 (93.9)
Lack of voice power30 (90.9)
Vocal fatigue and lack of vocal resistance32 (97.0)
Excess throat mucus during singing29 (87.9)
Throat or mouth dryness during singing25 (75.8)
Table 3. Test–retest reliability.
Table 3. Test–retest reliability.
Singer Reflux Symptom Score OutcomesTest–Retest rp-Value
Hoarseness0.6470.001
Abnormal voice breathiness0.9900.001
Difficulty to reach high pitch/notes0.6300.001
Additional effort during singing0.6790.001
Lack of voice power0.7290.001
Vocal fatigue and lack of vocal resistance0.7630.001
Excess throat mucus during singing0.5160.001
Throat or mouth dryness during singing0.5150.001
Singer Reflux Symptom total Score 0.7500.001
Table 4. Singer reflux symptom score internal validity and responsiveness to change.
Table 4. Singer reflux symptom score internal validity and responsiveness to change.
Baseline EvaluationsPost-Treatment (3 Months)
Singer Reflux Symptom Score OutcomesPatientsControlsZp-ValuePatientsZp-Value
Hoarseness14.9 ± 8.20.4 ± 3.0−8.600.0014.2 ± 5.6−2.240.025
Abnormal voice breathiness6.8 ± 8.10.1 ± 0.5−6.460.0011.6 ± 2.6−1.860.063
Difficulty to reach high pitch/notes15.9 ± 7.80.1 ± 3.3−8.160.0017.1 ± 9.2−2.190.028
Additional effort during singing13.9 ± 8.30.8 ± 3.3−7.690.0015.1 ± 7.1−2.240.025
Lack of voice power12.9 ± 9.20.7 ± 3.4−7.990.0013.7 ± 5.9−2.520.012
Vocal fatigue and lack of vocal resistance14.4 ± 8.20.7 ± 3.4−8.340.0015.7 ± 7.6−2.200.028
Excess throat mucus during singing11.4 ± 9.20.6 ± 2.7−8.320.0013.8 ± 5.5−2.370.018
Throat or mouth dryness during singing6.5 ± 7.50.1 ± 0.2−6.720.0011.5 ± 2.9−2.030.042
Total Singer Reflux Symptom Score96.6 ± 45.03.7 ± 11.0−7.870.00130.1 ± 37.4−2.930.003
SRSS—Quality-of-life21.1 ± 10.91.4 ± 3.1−7.170.0019.0 ± 9.4−2.190.028
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lechien, J.R. Validity and Reliability of the Singer Reflux Symptom Score (sRSS). J. Pers. Med. 2025, 15, 348. https://doi.org/10.3390/jpm15080348

AMA Style

Lechien JR. Validity and Reliability of the Singer Reflux Symptom Score (sRSS). Journal of Personalized Medicine. 2025; 15(8):348. https://doi.org/10.3390/jpm15080348

Chicago/Turabian Style

Lechien, Jérôme R. 2025. "Validity and Reliability of the Singer Reflux Symptom Score (sRSS)" Journal of Personalized Medicine 15, no. 8: 348. https://doi.org/10.3390/jpm15080348

APA Style

Lechien, J. R. (2025). Validity and Reliability of the Singer Reflux Symptom Score (sRSS). Journal of Personalized Medicine, 15(8), 348. https://doi.org/10.3390/jpm15080348

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop